Table 1.

Summary of the AEs reported during SAD and MAD

	Treated participants	Participants with possibly drug-related AEs	Participants with definitively drug-related AEs
SAD cohort (dose)	n	n	n
1 (200 mg)	4	0	0
2 (400 mg)	4	3a	0
3 (800 mg)	3	0	2b
MAD cohort (dose)	n	n	n
1 (200 mg)	6	5c	0
2 (300 mg)	6	4d	0
3 (400 mg)	6	5e	0

^aOne participant with mild, self-resolving diarrhoea, one with headache and one with tiredness. Mild, self-resolved AEs.

^bTwo with renal tubular damage, one of whom also had nausea and mild, self-resolving diarrhoea. Mild, self-resolved AEs.

^cTwo with headache, two with loose stools and one with lightheadedness. Mild, self-resolved AEs.

^dOne with headache, one with mild, self-resolving diarrhoea, one with abdominal pain and one with dysphagia. Mild, self-resolved AEs.

^eOne with constipation, one with soft stools, two with headaches and one with increased thirst. Mild, self-resolved AEs.